Welcome to our dedicated page for Zentek Ltd. news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek Ltd. (Nasdaq:ZTEK) has executed a property purchase agreement with its subsidiary, Albany Graphite Corp., to transfer the Albany Graphite Project. Albany will issue 59,999,900 common shares to Zentek in exchange for the ownership of the project, which includes mining claims and related assets. Albany plans to raise funds through a non-brokered private placement at $1.00 per subscription receipt, which will convert into common shares and warrants upon certain conditions being met. The funds will support community engagement, environmental studies, and an updated technical report. The Albany Graphite Project, located in Ontario, aims to supply a critical mineral for the Electric Vehicle industry, anticipating increased demand as projections suggest significant graphite production deficits in the coming decade.
Zentek Ltd. (NASDAQ: ZTEK, TSXV: ZEN) has announced the grant of 600,000 stock options to its directors, officers, and employees, exercisable at a price of $2.12 per share. The options will vest in stages over varying periods: one-third immediately, one-third after six months, and one-third after one year for executives, while others will vest one-third immediately, one-third after one year, and one-third after two years. This grant is part of the company’s annual compensation review. Zentek is a graphene technology company that develops products aimed at enhancing safety and performance, including the antimicrobial ZenGUARD™ coating, which has shown 99% efficacy against pathogens. The company’s production facility is in Guelph, Ontario. Further details can be found on their website and SEDAR profile.
Zentek Ltd. (NASDAQ:ZTEK) has filed patent applications for its antimicrobial technology, ZenGUARD, in 47 new jurisdictions, including the US and Europe. The patent examiner confirmed that ZenGUARD meets all requirements for patentability, including novelty and industrial applicability. This technology enhances the filtration efficiency of surgical masks and HVAC filters while exhibiting 99% antimicrobial activity. Zentek aims to commercialize ZenGUARD, asserting that it can provide significant competitive advantages to partners. The company also plans to pursue patents for additional technologies like ZenARMOR, focused on corrosion protection.
Zentek Ltd. (NASDAQ:ZTEK) has signed an agreement with Arka BRENStech Pvt Ltd to explore business opportunities in India, specifically targeting sales and distribution of Zentek's masks and HVAC filters. BRENStech will assist with regulatory navigation and connect Zentek with potential manufacturing partners. The Indian PPE market is valued at $1 billion USD, and Zentek has already shipped 2.1 million masks to support initial sales. With India's economy projected to become the 3rd largest by 2030 and a growing middle class, Zentek aims for significant growth in the region.
Zentek Ltd. (Nasdaq:ZTEK; TSXV:ZEN) announced successful antimicrobial testing for its ZenGUARD™-coated masks conducted by SGS. The testing showed over 99.99% bacterial filtration efficiency after just one hour. Specifically, the mask effectively reduced Escherichia Coli CFU from 260,000 to under 100. Additionally, ZenGUARD™ demonstrated 86.7% antiviral efficiency within one hour against H1N1, increasing to 99.7% after eight hours. These results highlight the potential of ZenGUARD™ to enhance safety for healthcare providers and patients in high-risk environments.
Zentek Ltd. (Nasdaq:ZTEK; TSX-V:ZEN) will have its CEO, Greg Fenton, present at the Industrial Tech Virtual Conference on March 21, 2023, at 2 p.m. ET. Hosted by Maxim Group LLC and available on M-Vest.com, the conference will address emerging technological trends in industrial sectors. Topics include drones, water infrastructure, solar project development, and clean energy technology. Zentek specializes in graphene and nanomaterials for healthcare applications, notably its ZenGUARD™ product, which demonstrates 99% antimicrobial efficacy. For more information, visit Zentek.com.
Zentek Ltd. (Nasdaq: ZTEK), an intellectual property development company, has announced the removal of outdated references to the Albany graphite deposit from its website upon request from the Ontario Securities Commission. This action relates to the 2015 economic analysis that is no longer deemed reliable. The company also revised its corporate presentation to eliminate unsupported statements and potential international partnerships until officially announced. Additionally, Zentek has filed a reciprocal supply agreement with Ekomed Global Inc. on SEDAR, which was due for filing with its Annual Information Form.
Zentek Ltd. (NASDAQ:ZTEK) announced a non-binding letter of intent with 1329307 BC Ltd. on February 13, 2023, to transfer its Albany Graphite Deposit to a new entity, SpinCo, which will be listed on a Canadian stock exchange. Management believes this move will help the project progress towards a prefeasibility study and unlock the asset's value, currently underappreciated in Zentek's share price. The transaction’s final structure will depend on consultations with advisors and requires various approvals. Zentek currently owns 100% of the deposit and aims for the separate entity to advance the project independent of its core operations.
Zentek Ltd. (NASDAQ:ZTEK, TSXV:ZEN) announced the development of ZenARMOR™, a novel corrosion protection technology utilizing functionalized Graphene Oxide. This innovative solution offers improved performance, self-healing properties, and potential environmental benefits due to its low active ingredient content. Third-party testing confirmed excellent corrosion resistance after 1,500 hours in ASTM B-117 tests. Zentek is pre-qualified for the Innovative Solutions Canada testing stream, having filed for a provisional patent and trademark for ZenARMOR™. The company aims to address the significant economic costs of corrosion, estimated at US$452 billion annually in the US.
Zentek Ltd. (Nasdaq:ZTEK), an intellectual property development company, announced the results of Phase 2 testing for its ZenGUARD™ technology in HVAC filtration. The ZenGUARD™ treated MERV 8 filters achieved a 34.56% filtration efficiency against the Phi6 virus, significantly improving from 7.24% in untreated filters. This advancement positions ZenGUARD™ as a potential game-changer for enhancing indoor air quality without incurring high costs for filter upgrades. Zentek is progressing towards commercialization, collaborating with federal organizations and seeking regulatory approvals in North America.
FAQ
What is the current stock price of Zentek Ltd. (ZTEK)?
What is the market cap of Zentek Ltd. (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
